Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients

Mutlu Dogan1*, Halil G Karabulut2, Ajlan Tukun2, Ahmet Demirkazik1, Gungor Utkan1, Bulent Yalcin1, Dilek Dincol1, Hakan Akbulut1, Fikri Icli1

Abstract

Introduction: Antimetabolites may cause severe toxicity and even toxic death in cancer patients. Our aim was to evaluate the relationship between antimetabolite toxicity and pharmacogenetics in patients with severe clinical toxicity or alanine transaminase (ALT) elevation after fluorouracil (5FU), capecitabine or methotrexate administration. Patients and Methods: Cancer patients with severe antimetabolite toxicity were evaluated for methylenetetrahydrofolate reductase (MTHFR) gene C667T, thymidilate synthase (TS) gene 5´UTR variable number of tandem repeats (VNTR), dihydroprymidine dehydrogenase (DPYD) gene IVS14+1G/A, Xeroderma pigmentosum (XPD) gene Lys751Gln and X-ray repair cross-complementing group 1 (XRCC1) gene Arg399Gln polymorphisms. Results: Eighteen patients were enrolled, with a male/female ratio of 0.8. They had osteosarcoma in methotrexate group (n=7), gastrointestinal malignancies in 5FU group (n=9) and breast cancer in the capecitabine group (n=2). Mucositis and dermatitis occurred in all groups, together with ALT elevation in the methotrexate group and 2 toxic deaths were encountered. DPYD, TS, MTHFR, XPD and XRCC1 gene polymorphism rare allele frequencies were observed to be higher than in the general population. Conclusion: Pharmacogenetics might contribute to tailored therapy.

Keywords: Pharmacogenetics - antimetabolite toxicity - methotrexate - fluorouracil

Asian Pacific J Cancer Prev, 13, 1553-1556

Introduction

Antimetabolites may cause severe toxicities, even lethal toxicities, in some of the cancer patients receiving chemotherapy (CT) including antimetabolites, like methotrexate and 5-fluorouracil (5FU). Rate of severe toxicity with 5FU-based chemotherapy was reported as 30% in a meta-analysis (Meta-analysis group in cancer, 1998).

5FU inhibits thymidilate synthase (TS), an enzyme which converts deoxyuridylate to thymidylate. Methotrexate inhibits tetrahydrofolate generation by dihydrofolate reductase. Tetrahydrofolate has role in carbon unit transfer which is essential for thymidylate synthesis. Therefore, both 5FU and methotrexate disturb DNA synthesis via TS inhibition. TS activity can also be measured in peripheral mononuclear cells, and DPYD mutations leading to decreased enzyme activity can be analyzed by genotyping.

Methotrexate is an antifolate agent. It is commonly used in the treatment of leukemia, lymphoma and almost in all cases of osteosarcoma. 5,10-methylenetetrahydrofolate reductase (MTHFR) is involved in maintaining folic acid homeostasis and converts 5,10-metylenetetrahydrofolate to 5-metylenetetrahydrofolate (Kantar et al, 2009). MTHFR gene is located on 1p36.13 (Goyette et al, 1998). C677T and A1298C polymorphisms are well-known MTHFR gene polymorphisms both of which cause to decrease enzyme activity and lower folate levels (Toffoli et al, 2008).

DNA repair genes, such as xeroderma pigmentosum group D (XPD) and X-ray repair cross-complementing group 1 (XRCC1), have roles in genomic stability via DNA repair pathways, like nucleotide excision repair, base excision repair and double-strand break repair (Sreeja et al 2008; López-Cima et al 2007). Gene polymorphisms may occur at codon 194, 280 and 399 for XRCC1 whereas they may occur at codon 512 and 751 for XPD. Arg399Gln (substitution of Arg with Gln) and Lys751Gln (substitution of Lys wiyh Gln) are well-known gene polymorphisms

1Dept of Medical Oncology, 2Dept of Medical Genetics, School of Medicine, Ankara University, Ankara, Turkey *For correspondence: mutludogan1@yahoo.com
for XRCC1 and XPD, respectively. However, the effect of DNA repair gene polymorphisms in cancer promotion or progression is controversial (López-Címa et al 2007; Sliwinski et al 2009; Wang et al 2009).

MTFHR gene T allele increases both methotrexate toxicity risk and 5FU response rate. DPYD A allele also increases risk of 5FU toxicity while TS 3R, XPD Gln and XRCC1 Gln alleles decrease 5FU response or increase 5FU resistance. Therefore, all these gene polymorphisms have relevant importance in pharmacogenetic analysis of patients to be treated with these drugs. Tailored therapy based on pharmacogenetic data may provide the administration of the most appropriate and cost-effective treatment with less toxicity.

The aim of this study was to define these polymorphisms which might have been related to antimetabolite toxicity and response to the treatment in a group of patients who had suffered from grade 3-4 clinical or biochemical toxicity.

Materials and Methods

The patients who had suffered from grade 3-4 clinical or biochemical toxicity were analyzed for gene polymorphisms which might have been related to toxicity. DNA was isolated from peripheral blood samples by standard salting-out extraction.

MTHFR gene C667T and TS gene 5’UTR VNTR polymorphisms were investigated for methotrexate toxicity. TS gene 5’UTR VNTR, DPYD gene IVS14+1G/A, MTFHR gene C667T, XPD gene Lys751Gln and XRCC1 gene Arg399Gln polymorphisms were analyzed for 5FU efficacy and toxicity. TS polymorphism was evaluated by polymerase chain reaction (PCR) while DPYD, MTHFR, XPD and XRCC1 polymorphisms were evaluated by PCR-RFLP.

Results

Eighteen patients were enrolled between January 2008 and November 2008. Patient characteristics are summarized in table 1. Most of the patients were female (10/18), but methotrexate and 5FU groups had male predominance. Gene polymorphisms and treatment toxicities in our patient group are shown in Table 2, and frequencies of common and rare alleles of these polymorphisms in our patient group and general population are given in Table 3.

In methotrexate group, the most common toxicity was liver toxicity (i.e. ALT elevation). In this group, five patients had ALT elevation, one patient had high ALT level with grade 4 mucositis and another one had grade 3 mucositis. Median methotrexate cycle (12g/m2, max 20g/d, on days 21 and 28, every 5 weeks) was 2 (range=1-3) with a median interval between methotrexate administration and toxicity onset as 2 days (1-6). Median methotrexate level at 24h was 9.05 µmol/L (1.45-32, N<10). Median ALT level was 854 U/L (248-2885, N<40) with median increment as 22.4-fold (6.2-72,1). MTHFR gene T allele frequency was 47.2% in our patients who had methotrexate toxicity. Population frequency of this rare allele is 10-40%.

In 5FU / capecitabine group, nine patients had grade 4 mucositis, one patient had grade 4 mucositis with grade

| Table 2. Characteristics with Gene Polymorphisms of the Patients. |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| No. | DPD | TS | MTFHR | XPD | XRCC1 | Treatment ALT level | Toxicity (X UL) | Max ALT level | 24h Mtx Interval between ALT peak and Mtx |
| 1 | GG | 3R/3R | CT | Gln/Lys | Arg/Gln | capcitabine | mucositis/dermatitis | - | - | - |
| 2 | GG | 2R/3R | CT | ? | ? | 5FU | mucositis | - | - | - |
| 3 | GA | 2R/2R | CT | Lys/Gln | Gln/Gln | 5FU | mucositis | - | - | - |
| 4 | GG | 2R/3R | CT | Lys/Lys | Arg/Gln | capcitabine | mucositis | - | - | - |
| 5 | GG | 3R/3R | CT | Lys/Gln | Arg/Arg | 5FU | mucositis | - | - | - |
| 6 | GG | 2R/2R | CT | Lys/Gln | Arg/Arg | 5FU | mucositis | - | - | - |
| 7 | GG | 2R/2R | CT | Lys/Gln | Arg/Gln | 5FU | mucositis | - | - | - |
| 8 | GG | 2R/2R | CT | Lys/Gln | Arg/5FU | mucositis | - | - | - |
| 9 | GG | 2R/3R | CC | Lys/Lys | Arg/5FU | mucositis | - | - | - |
| 10 | GG | 3R/3R | TT | Gln/Gln | Arg/5FU | mucositis-FEN** | - | - | - |
| 11 | GG | 2R/3R | CT | Gln/Gln | Arg/5FU | mucositis | - | - | - |
| 12 | - | 3R/3R | TT | - | - | meth* | - | - | - |
| 13 | - | 3R/3R | CT | - | - | mtx | High ALT | 279 | 6.97 | 18.94 |
| 14 | - | 2R/3R | CT | - | - | mtx | High ALT | 962 | 24 | 9.05 |
| 15 | - | 3R/3R | CC | - | - | mtx | High ALT | 945 | 23.6 | 4.93 |
| 16 | - | 2R/3R | CT | - | - | mtx | High ALT | 854 | 21.3 | 2.9 |
| 17 | - | 3R/3R | CC | - | - | mtx | High ALT | 248 | 6.2 | 1.45 |
| 18 | - | 2R/3R | CT | - | - | mtx | High ALT | 2885 | 72.1 | 32 |

* methotrexate, ** febrile neutropenia # toxic deaths
Table 3. Common and Rare Allele Frequencies of Genetic Polymorphisms in Patients Compared with the Population.

| Gene   | Allele | Population (%) | Our study (%) | Allele | Population (%) | Our study (%) |
|--------|--------|----------------|--------------|--------|----------------|--------------|
| DPYD   | IVS14+1G | 99            | 95.5         | 1      | IVS14+1A       | 1            | 4.5          |
| TS     | 3R     | 60-80         | 55.5         | 2R     | 20-40          | 44.5         |
| MTHFR  | C667   | 60-90         | 52.8         | 667T   | Oct-40         | 47.2         |
| XPD    | Lys751 | 70-72         | 55           | 751Gln | 28-30          | 45           |

4 dermatitis (hand-foot syndrome) and another one had grade 4 mucositis with febrile neutropenia (grade 4). DPYD IVS14+1A allele frequency was 4.5 fold higher than population. TS common allele (3R) frequency was found to be slightly lower in our patient group. On the other hand, it showed differences between 5FU and methotrexate groups; it was lower in 5FU group but in normal population range in methotrexate group.

For XPD and XRCC1 gene polymorphisms associated with decreased 5FU response, the frequency of Gln alleles for both genes was found to be 45% which is higher than the population frequency.

There were two toxic deaths. The first patient had 5FU, cisplatin and docetaxel for advanced stage gastric cancer. He had disseminated grade 4 mucositis after first cycle of CT. Co-administration of docetaxel with 5FU might have contributed to grade 4 mucositis. He had been applied supportive care including total parenteral nutrition. He died because of sepsis. The second patient was given 5FU, folinic acid and oxaliplatin (FOLFOX-4 regimen) for colorectal cancer. He suffered from grade 4 neutropenia and grade 4 mucositis. He died because of febrile neutropenia in spite of supportive care including parenteral antibiotics.

Discussion

Thirty-nine different mutations and polymorphisms leading to decreased enzyme activity and therefore to increased risk of toxicity for 5-FU have been identified in DPYD gene with an overall heterozygote frequency of 3 % (Van Kuilenburg 2004; Dervieux 2005). The most frequent inactivating mutation is IVS14+1G>A leading to skipping exon 14 and therefore missing 165 nucleotide in mRNA and the corresponding 55 aminoacids in the protein product. The frequency of IVS14+1G>A mutation in patients with severe toxicity after 5-FU treatment is controversial. Van Kuilenburg et al. reported that the frequency of IVS14+1G>A mutation was 50 % in patients with grade IV neutropenia either in homozygote or heterozygote state and was 56 % in patients with low DPYD level (Van Kuilenburg, 2002). However, Magnè et al. reported the frequency of the same mutation as low as 2.2 % in a group of patient with 5FU-related toxicity and concluded that screening for IVS14+1G>A mutation have limited effectiveness in identifying patients at risk, at least for French population (Magnè et al., 2007). Recently, Gross et al. reported another mutation, c.496A>G with a high frequency of 43 % in patients with severe drug-adverse effects while the frequency of IVS14+1G>A mutation was found to be as low as 5.4 % (Gross et al., 2008). Furthermore, association of C496A>G mutation with toxicity was observed in patients with gastroesophageal and breast cancer but not in patients with colorectal malignancies. In our study, IVS14+1G>A mutation was found in only one case in heterozygote state with an overall frequency of 4.5 % (n=11) which is still 4.5 fold higher than the population frequency. The discrepancy between the results of individual studies has been attributed to ethnic differences of patients, different therapy regimens and tumor type (Magnè et al 2007; Gross et al 2008). Moreover, it was suggested that not only a few mutations but all functionally important mutations and polymorphisms must be screened in order to identify patients at risk for 5-FU related toxicity. Magnè et al. also suggested the need for the development of a large scale screening test for DPYD with good sensitivity and specificity by using genetic and/or biochemical techniques (Magnè et al., 2007). However, also the efficacy of 5-FU is effected by the functional polymorphisms of genes encoding metabolizing enzymes. The main target of 5-FU is the enzyme thymidilate synthase and higher levels of this enzyme is associated with reduced response to 5-FU treatment. Since TS gene 3R allele is related to the elevated expression of TS, individuals with 3R allele are less likely to respond to 5-FU. On the other hand, higher levels of MTHF increase the inhibitory effect of 5-FU. MTHF is the substrate of MTHFR and since MTHFR 677T allele reduces the activity of the enzyme and therefore cause an increase in the MTHF levels, individuals with T allele have e better response to 5-FU. In our study, TS 3R allele frequency was found to be lower than the population frequency in 5FU group while MTHFR T allele frequencies were found to be higher. Taken together, 5FU toxicity may be due to the increased efficacy of 5FU as a result of increased TS 2R and MTHFR T allele frequencies. However, a second polymorphism, a G>C single nucleotide polymorphism, in the second repeat of the 3R allele dramatically effects the expression level of this allele in a way that 3R alleles harboring C nucleotide (named as 3RC allele) have the same expression level of 2R allele while 3R alleles with G nucleotide (named as 3RG allele) have a higher level of expression. As a result, 3R/3R genotype does not necessarily mean higher expression levels. It may be significant to investigate G>C polymorphism in 3R/3R genotypes. Furthermore, a third polymorphism, a 6 bp deletion in 3’ untranslated region, was found to be associated with 5-FU response in such a way that 3R/-6bp alleles had a better response. In MTHFR gene, a second polymorphism, 1298A>C namely, also reduces the activity of the enzyme and has a better response to 5-FU.

Analysis of all relevant polymorphisms associated with the efficacy and toxicity of a given drug is recommended as a pharmacogenetic approach to clarify the efficacy and toxicity of therapeutic agents (Toffoli...
In conclusion, antimetabolites are widely used in cancer patients. Some patients may have higher rates of toxicity, even lethal toxicity. We consider that pharmacogenomic analysis might contribute to individualized therapy (‘tailored therapy’). It will not only increase response rates but also decrease toxicity. Individualized therapy will be also cost-effective by avoiding administration of unnecessary chemotherapy to the patients who will have no benefit. It should be emphasized that we only analyzed gene polymorphisms of the patients who had severe toxicity. We evaluated gene polymorphisms after toxicity. However, it will be better if suitable patients are selected before CT. We believe that we need further pharmacogenetic trials with more patients to have better clinical outcome.

References

Campalani E, Arenas M, Marinaki M, et al (2007). Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol, 127, 1860-7.

Dervieux T, Meshkin B, Neri B (2005). Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res, 573, 180-94.

Goyette P, Pai A, Milos R, et al (1998). Gene structure of human and mouse methylenetetrahydrofolate reductase. Mamm Genome, 9, 652-6.

Gross E, Busse B, Riemenschneider M, et al (2008). Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One, 3, e4003, 1-7.

Kantar M, Kosova B, Cetingul N, et al (2009). Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma, 50, 912-7.

López-Cima MF, González-Arriaga P, García-Castro L, et al (2007). Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer, 7, 162-73.

Magné N, Etienne-Grimaldi MC, Cals L, et al (2007). Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol, 64, 237-40.

Meta-Analysis Group in Cancer (1998). Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol, 16, 3537–41.

Sliwinski T, Krupa R, Wisniewska-Iarosinska M et al (2009). Common polymorphisms in the XPD and hOGG1 genes are not associated with the risk of colorectal cancer in a Polish population. Tohoku J Exp Med, 218, 185-91.

Sreeja L, Syamala VS, Syamala V, et al (2008). Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol, 134, 645-52.

Toffoli G, de Mattia E (2008). Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics, 9, 1195-206.

Van Kuilenburg AB, Haasjes J, Richel DJ, et al (2000). Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluourouracil-associated Toxicity: Identification of New Mutations in the DPD Gene. Clinical Cancer Research, 6, 4705-12.

Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002). Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14-1G-A mutation. Int J Cancer, 101, 253-8.

Van Kuilenburg AB (2004). Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer, 40, 939-50.

Wang M, Gu D, Zhang Z, et al (2009). XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A, 72, 698-05.